Cargando…
ML216-Induced BLM Helicase Inhibition Sensitizes PCa Cells to the DNA-Crosslinking Agent Cisplatin
Using standard DNA-damaging medicines with DNA repair inhibitors is a promising anticancer tool to achieve better therapeutic responses and reduce therapy-related side effects. Cell viability assay, neutral comet assay, western blotting (WB), and cell cycle and apoptosis analysis were used to determ...
Autores principales: | Ma, Xiao-Yan, Zhao, Jia-Fu, Ruan, Yong, Zhang, Wang-Ming, Zhang, Lun-Qing, Cai, Zheng-Dong, Xu, Hou-Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788632/ https://www.ncbi.nlm.nih.gov/pubmed/36557923 http://dx.doi.org/10.3390/molecules27248790 |
Ejemplares similares
-
ML216 Prevents DNA Damage-Induced Senescence by Modulating DBC1–BLM Interaction
por: Cui, Feng, et al.
Publicado: (2022) -
Downregulation of BLM RecQ helicase inhibits proliferation, promotes the apoptosis and enhances the sensitivity of bladder cancer cells to cisplatin
por: Feng, Sujuan, et al.
Publicado: (2022) -
Mycobacterial helicase Lhr abets resistance to DNA crosslinking agents mitomycin C and cisplatin
por: Warren, Garrett M, et al.
Publicado: (2023) -
Structural mechanisms of human RecQ helicases WRN and BLM
por: Kitano, Ken
Publicado: (2014) -
hSSB1 associates with and promotes stability of the BLM helicase
por: Croft, Laura V., et al.
Publicado: (2017)